The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma

A. Escribano, A. Tutuncu, I. Lohr, M. Carlholm, T. Polanowski (Valencia, Spain; Muttenz, Switzerland; Lund, Sweden)

Source: Annual Congress 2005 - Paediatric asthma drug therapy
Session: Paediatric asthma drug therapy
Session type: Thematic Poster Session
Number: 1051
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Escribano, A. Tutuncu, I. Lohr, M. Carlholm, T. Polanowski (Valencia, Spain; Muttenz, Switzerland; Lund, Sweden). The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma. Eur Respir J 2005; 26: Suppl. 49, 1051

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: